Economic evaluation of eribulin as second-line treatment for metastatic breast cancer in South Korea

BACKGROUND: Metastatic breast cancer (MBC) is associated with poor prognosis, particularly for those patients with human epidermal growth factor receptor (HER2)-negative tumor. Similar to the rest of the world, treatment options are limited in South Korea following first-line chemotherapy with anthr...

Descripción completa

Detalles Bibliográficos
Autores principales: Tremblay, Gabriel, Majethia, Unnati, Breeze, Janis L, Kontoudis, Ilias, Park, Jeongae
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2016
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5034912/
https://www.ncbi.nlm.nih.gov/pubmed/27698565
http://dx.doi.org/10.2147/CEOR.S110553

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5034912/
https://www.ncbi.nlm.nih.gov/pubmed/27698565
http://dx.doi.org/10.2147/CEOR.S110553

Ejemplares similares